Table 1 Demographic and baseline characteristics
Parameter | Placebo (n = 21) | Volixibat | |||||||
|---|---|---|---|---|---|---|---|---|---|
5 mg b.i.d. (n = 9) | 10 mg = q.d. (n = 9) | 20 mg q.d. (n = 9) | 2–5–10–20 mg q.d. (n = 9) | 30 mg q.d. (n = 9) | 40 mg q.d. (n = 9) | 80–40–20 mg q.d. (n = 9) | Total (n = 63) | ||
Age, years | 41.5 (9.47) | 37.1 (15.40) | 46.2 (7.61) | 33.3 (9.82) | 46.2 (7.82) | 44.6 (10.70) | 36.6 (8.92) | 33.2 (11.34) | 39.6 (11.41) |
Men, n (%) | 18 (85.7) | 9 (100) | 7 (77.8) | 9 (100) | 9 (100) | 8 (88.9) | 9 (100) | 9 (100) | 60 (95.2) |
BMI, kg/m2 | 29.65 (1.426) | 27.81 (1.614) | 29.53 (2.087) | 29.49 (2.587) | 29.67 (3.399) | 30.96 (1.368) | 28.91 (1.898) | 29.27 (2.971) | 29.38 (2.422) |
Race, n (%) | |||||||||
 White | 8 (38.1) | 4 (44.4) | 4 (44.4) | 4 (44.4) | 7 (77.8) | 3 (33.3) | 9 (100) | 4 (44.4) | 35 (55.6) |
 Black or African American | 12 (57.1) | 5 (55.6) | 5 (55.6) | 5 (55.6) | 2 (22.2) | 6 (66.7) | 0 | 5 (55.6) | 28 (44.4) |
 American Indian or Alaska native | 1 (4.8) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |